Ting Wei1, Manjun Li2, Zhigang Zhu3, Huabao Xiong4, Han Shen1, Hui Zhang4, Qinghua Du1, Qingshan Li5,6. 1. Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, People's Republic of China. 2. Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, Guangdong Province, People's Republic of China. 3. Department of Geriatrics, Hematology and Oncology ward, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, People's Republic of China. 4. Institute of Immunology and Molecular Medicine, Jining Medical University, Jinan, 272067, Shandong, People's Republic of China. 5. Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, People's Republic of China. eyqingshanli@scut.edu.cn. 6. Department of Hematology, Guangzhou Red Cross Hospital, Jinan University, No.396 TongFu Middle Road, Haizhu District, Guangzhou, 510220, Guangdong, People's Republic of China. eyqingshanli@scut.edu.cn.
Abstract
BACKGROUND: Some chemotherapy drugs have immunomodulatory effects on specific tumors. The potential of vincristine (VCR) in the R-CHOP regimen to act as both a chemotherapeutic and an immunomodulatory agent via PD-L1 in tumor cells remains unclear. METHODS: In vitro screening VCR showed that the IC50 value of VCR in the DLBCL cell lines was approximately 2 nM. Western blotting and q-PCR were used to detect the expression of PD-L1. The effect of VCR combined with PD-L1 mAb was tested in a co-culture system of LY-OCI-3 cells and peripheral blood mononuclear cells and in DLBCL xenograft mouse model. Flow cytometry was used to determine the proportion of T lymphocyte subsets. The effect of the STAT3 inhibitor nifuroxazide on VCR-induced PD-L1 expression was tested in LY-OCI-3 and SU-DHL-4 cells. RESULTS: VCR upregulated PD-L1 protein and mRNA expression in various DLBCL cell lines. PD-L1 Ab combined with VCR significantly increased the proportion of CD8 + Granzyme B + , INF-γ + or TNF-α + CD3 + T cells. VCR + PD-L1 Ab inhibited tumor growth more effectively than VCR monotherapy, whereas PD-L1 Ab alone had no significant effect. Survival time did not differ significantly between the PD-L1 Ab group and the control group, whereas it was significantly longer in the VCR monotherapy and combination groups which showed more longer survival compared with the former. Nifuroxazide downregulated p-STAT3 and PD-L1 protein levels. CONCLUSIONS: VCR upregulated PD-L1 expression in DLBCL cells partially by promoting the p-STAT3; VCR combined with PD-L1 Ab activated effector T cells and increased the antitumor immune response in vitro and in vivo.
BACKGROUND: Some chemotherapy drugs have immunomodulatory effects on specific tumors. The potential of vincristine (VCR) in the R-CHOP regimen to act as both a chemotherapeutic and an immunomodulatory agent via PD-L1 in tumor cells remains unclear. METHODS: In vitro screening VCR showed that the IC50 value of VCR in the DLBCL cell lines was approximately 2 nM. Western blotting and q-PCR were used to detect the expression of PD-L1. The effect of VCR combined with PD-L1 mAb was tested in a co-culture system of LY-OCI-3 cells and peripheral blood mononuclear cells and in DLBCL xenograft mouse model. Flow cytometry was used to determine the proportion of T lymphocyte subsets. The effect of the STAT3 inhibitor nifuroxazide on VCR-induced PD-L1 expression was tested in LY-OCI-3 and SU-DHL-4 cells. RESULTS:VCR upregulated PD-L1 protein and mRNA expression in various DLBCL cell lines. PD-L1 Ab combined with VCR significantly increased the proportion of CD8 + Granzyme B + , INF-γ + or TNF-α + CD3 + T cells. VCR + PD-L1 Ab inhibited tumor growth more effectively than VCR monotherapy, whereas PD-L1 Ab alone had no significant effect. Survival time did not differ significantly between the PD-L1 Ab group and the control group, whereas it was significantly longer in the VCR monotherapy and combination groups which showed more longer survival compared with the former. Nifuroxazide downregulated p-STAT3 and PD-L1 protein levels. CONCLUSIONS:VCR upregulated PD-L1 expression in DLBCL cells partially by promoting the p-STAT3; VCR combined with PD-L1 Ab activated effector T cells and increased the antitumor immune response in vitro and in vivo.
Authors: Shanshan Deng; Raisa I Krutilina; Qinghui Wang; Zongtao Lin; Deanna N Parke; Hilaire C Playa; Hao Chen; Duane D Miller; Tiffany N Seagroves; Wei Li Journal: Mol Cancer Ther Date: 2019-10-23 Impact factor: 6.261
Authors: E J Aguilar; B Ricciuti; J F Gainor; K L Kehl; S Kravets; S Dahlberg; M Nishino; L M Sholl; A Adeni; S Subegdjo; S Khosrowjerdi; R M Peterson; S Digumarthy; C Liu; J Sauter; H Rizvi; K C Arbour; B W Carter; J V Heymach; M Altan; M D Hellmann; M M Awad Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245
Authors: Toby A Eyre; Catherine Hildyard; Angela Hamblin; Ayesha S Ali; Aimee Houlton; Louise Hopkins; Daniel Royston; Kim M Linton; Andrew Pettitt; Simon Rule; Kate Cwynarski; Sally F Barrington; Victoria Warbey; David Wrench; Sharon Barrans; Caroline S Hirst; Anesh Panchal; Martine P Roudier; Elizabeth A Harrington; Andrew Davies; Graham P Collins Journal: Hematol Oncol Date: 2019-09-09 Impact factor: 5.271
Authors: Paul A Fields; William Townsend; Andrew Webb; Nicholas Counsell; Christopher Pocock; Paul Smith; Andrew Jack; Nadjet El-Mehidi; Peter W Johnson; John Radford; David C Linch; David Cunnningham Journal: J Clin Oncol Date: 2013-11-12 Impact factor: 44.544
Authors: S Ciavarella; M C Vegliante; M Fabbri; S De Summa; F Melle; G Motta; V De Iuliis; G Opinto; A Enjuanes; S Rega; A Gulino; C Agostinelli; A Scattone; S Tommasi; A Mangia; F Mele; G Simone; A F Zito; G Ingravallo; U Vitolo; A Chiappella; C Tarella; A M Gianni; A Rambaldi; P L Zinzani; B Casadei; E Derenzini; G Loseto; A Pileri; V Tabanelli; S Fiori; A Rivas-Delgado; A López-Guillermo; T Venesio; A Sapino; E Campo; C Tripodo; A Guarini; S A Pileri Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976